Compare Biogen Inc (BIIB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Zimmer Biomet Holdings Inc — how do they compare? Biogen Inc trades at $191.9 (market cap $30.86B), while Zimmer Biomet Holdings Inc trades at $90.5 (market cap $18.20B). The key difference: Biogen Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ZBH | |
|---|---|---|
Market Cap | $30.86B | $18.20B |
Sector | Health | Health |
52-Week High | $216.63 | $107.71 |
52-Week Low | $122.68 | $79.58 |
Enterprise Value | $33.14B | $25.25B |
Dividend Yield | — | 1.02% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
